肺动脉高压中的肺血管重塑
Pulmonary vascular remodeling in pulmonary hypertension.
作者信息
Tuder Rubin M
机构信息
Program in Translational Lung Research, Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus Research 2, Room 9001, 12700 East 19th Avenue, Aurora, CO 80045, USA.
出版信息
Cell Tissue Res. 2017 Mar;367(3):643-649. doi: 10.1007/s00441-016-2539-y. Epub 2016 Dec 26.
Abstract
Pulmonary vascular remodeling is the key structural alteration in pulmonary hypertension and involves changes in the intima, media and adventitia, often with the interplay of inflammatory cells. This review examines the pathology of these changes and highlights some of the pathogenetic mechanisms that underlie the remodeling process.
摘要
肺血管重塑是肺动脉高压的关键结构改变，涉及内膜、中膜和外膜的变化，常伴有炎症细胞的相互作用。本综述探讨了这些变化的病理学，并强调了重塑过程背后的一些发病机制。
相似文献
1
Pulmonary vascular remodeling in pulmonary hypertension.肺动脉高压中的肺血管重塑
Cell Tissue Res. 2017 Mar;367(3):643-649. doi: 10.1007/s00441-016-2539-y. Epub 2016 Dec 26.
2
Pathology of pulmonary hypertension.肺动脉高压的病理学。
Clin Chest Med. 2013 Dec;34(4):639-50. doi: 10.1016/j.ccm.2013.08.009. Epub 2013 Oct 17.
3
Pulmonary hypertension and vascular remodeling in mice exposed to crystalline silica.暴露于结晶二氧化硅的小鼠中的肺动脉高压和血管重塑。
Respir Res. 2016 Nov 28;17(1):160. doi: 10.1186/s12931-016-0478-5.
4
Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension.肺动脉高压中肺血管重塑的分子和细胞基础
Prog Cardiovasc Dis. 2002 Nov-Dec;45(3):173-202. doi: 10.1053/pcad.2002.130041.
5
Pulmonary Vascular Remodeling in Pulmonary Hypertension.肺动脉高压中的肺血管重塑
J Pers Med. 2023 Feb 19;13(2):366. doi: 10.3390/jpm13020366.
6
Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension.肺动脉高压中血管平滑肌细胞功能特性的动态和多样化变化。
Cardiovasc Res. 2018 Mar 15;114(4):551-564. doi: 10.1093/cvr/cvy004.
7
NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.NMDA 型谷氨酸受体激活促进血管重塑和肺动脉高压。
Circulation. 2018 May 29;137(22):2371-2389. doi: 10.1161/CIRCULATIONAHA.117.029930. Epub 2018 Feb 14.
8
Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.代谢重编程与炎症协同作用，以控制低氧性肺动脉高压中的血管重塑。
J Appl Physiol (1985). 2015 Nov 15;119(10):1164-72. doi: 10.1152/japplphysiol.00283.2015. Epub 2015 Apr 30.
9
New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.肺动脉高压中肺血管重塑的新分子靶点：内皮细胞通讯的重要性
Chest. 2015 Feb;147(2):529-537. doi: 10.1378/chest.14-0862.
10
Fibroblasts in Pulmonary Hypertension: Roles and Molecular Mechanisms.肺高血压中的成纤维细胞：作用和分子机制。
Cells. 2024 May 25;13(11):914. doi: 10.3390/cells13110914.
引用本文的文献
1
SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension.SUL-150可限制肺动脉高压中的血管重塑和心室衰竭。
Int J Mol Sci. 2025 Jul 25;26(15):7181. doi: 10.3390/ijms26157181.
2
Dynamic and interpretable deep learning model for predicting respiratory failure following cardiac surgery.用于预测心脏手术后呼吸衰竭的动态可解释深度学习模型
BMC Anesthesiol. 2025 Aug 5;25(1):394. doi: 10.1186/s12871-025-03239-z.
3
State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment.肺动脉高压的最新进展：分子基础、成像方式及右心衰竭治疗
Biomedicines. 2025 Jul 20;13(7):1773. doi: 10.3390/biomedicines13071773.
4
Pterostilbene mitigates experimental pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition.紫檀芪通过抑制内皮-间充质转化减轻实验性肺动脉高压。
Front Pharmacol. 2025 Jun 25;16:1621700. doi: 10.3389/fphar.2025.1621700. eCollection 2025.
5
The Impact of Antenatal and Postnatal Factors on the Development of the Pulmonary Microvasculature in Preterm Infants.产前和产后因素对早产儿肺微血管发育的影响。
Children (Basel). 2025 May 18;12(5):650. doi: 10.3390/children12050650.
6
Prevalence and Economic Burden of Pulmonary Hypertension and Pulmonary Arterial Hypertension Among the Medicaid Population.医疗补助人群中肺动脉高压和动脉性肺动脉高压的患病率及经济负担
Pulm Circ. 2025 Apr 17;15(2):e70060. doi: 10.1002/pul2.70060. eCollection 2025 Apr.
7
RNA-binding proteins as a molecular link between COPD and pulmonary hypertension.RNA结合蛋白作为慢性阻塞性肺疾病与肺动脉高压之间的分子纽带
Int J Med Sci. 2025 Mar 29;22(8):1979-1991. doi: 10.7150/ijms.108587. eCollection 2025.
8
Localization, Proteolytic Processing, and Binding Partners of Versican Isoforms in Vascular Lesions of Pulmonary Arterial Hypertension.多功能蛋白聚糖异构体在肺动脉高压血管病变中的定位、蛋白水解加工及结合伴侣
J Histochem Cytochem. 2025 Mar-Apr;73(3-4):129-145. doi: 10.1369/00221554251331271. Epub 2025 Apr 11.
9
Connexin 43 Affects Pulmonary Artery Reactivity via Changes in Nitric Oxide Production and Influences Proliferative and Migratory Responses in Mouse Pulmonary Artery Fibroblasts.连接蛋白43通过一氧化氮生成的变化影响肺动脉反应性，并影响小鼠肺动脉成纤维细胞的增殖和迁移反应。
Int J Mol Sci. 2025 Feb 1;26(3):1280. doi: 10.3390/ijms26031280.
10
Sotatercept and pulmonary arterial hypertension.索他洛尔与肺动脉高压。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49(9):1503-1508. doi: 10.11817/j.issn.1672-7347.2024.240093.
本文引用的文献
1
The Causal Role of IL-4 and IL-13 in Schistosoma mansoni Pulmonary Hypertension.白细胞介素-4和白细胞介素-13在曼氏血吸虫性肺动脉高压中的因果作用
Am J Respir Crit Care Med. 2015 Oct 15;192(8):998-1008. doi: 10.1164/rccm.201410-1820OC.
2
Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.代谢重编程与炎症协同作用，以控制低氧性肺动脉高压中的血管重塑。
J Appl Physiol (1985). 2015 Nov 15;119(10):1164-72. doi: 10.1152/japplphysiol.00283.2015. Epub 2015 Apr 30.
3
The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes.炎症在低氧性肺动脉高压中的作用：从细胞机制到临床表型。
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 1;308(3):L229-52. doi: 10.1152/ajplung.00238.2014. Epub 2014 Nov 21.
4
How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease.我们如何测量 PAH（肺和 RV）中的病理学，它能告诉我们关于疾病的哪些信息。
Drug Discov Today. 2014 Aug;19(8):1257-63. doi: 10.1016/j.drudis.2014.05.022. Epub 2014 May 29.
5
Relevant issues in the pathology and pathobiology of pulmonary hypertension.肺动脉高压病理与病理生理学相关问题。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D4-12. doi: 10.1016/j.jacc.2013.10.025.
6
Updated clinical classification of pulmonary hypertension.肺动脉高压的最新临床分类。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029.
7
Pathology of pulmonary hypertension.肺动脉高压的病理学。
Clin Chest Med. 2013 Dec;34(4):639-50. doi: 10.1016/j.ccm.2013.08.009. Epub 2013 Oct 17.
8
Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract.肺部定量显微镜检查：基于问题的方法。第 2 部分：呼吸道各种疾病的体视学参数和研究设计。
Am J Physiol Lung Cell Mol Physiol. 2013 Aug 1;305(3):L205-21. doi: 10.1152/ajplung.00427.2012. Epub 2013 May 24.
9
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.免疫和炎症细胞在特发性肺动脉高压病理中的作用。
Am J Respir Crit Care Med. 2012 Nov 1;186(9):897-908. doi: 10.1164/rccm.201202-0335OC. Epub 2012 Sep 6.
10
Modern age pathology of pulmonary arterial hypertension.肺动脉高压的现代病理学。
Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72. doi: 10.1164/rccm.201201-0164OC. Epub 2012 Jun 7.
Zotero 插件